Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

Abstract

A cytokine that can synergize with interleukin 2 to activate cytotoxic lymphocytes was purified to homogeneity. The protein, provisionally called cytotoxic lymphocyte maturation factor (CLMF), was isolated from a human Blymphoblastoid cell line that was induced to secrete lymphokines by culture with phorbol ester and calcium ionophore. The purification method, utilizing classical and high-performance liquid chromatographic techniques, yielded protein with a specific activity of 8.5 x 107 units/mg in a T-cell growth factor assay. Analysis of the purified protein by sodium dodecyl sulfate/polyacrylamide gel electrophoresis demonstrated that CLMF is a 75-kDa heterodimer composed of disulfide-bonded 40-kDa and 35-kDa subunits. Determination of the N-terminal amino acid sequences of the two subunits revealed that both subunits are not related to any previously identified cytokine. Purified CLMF stimulated the proliferation of human phytohemagglutinin-activated lymphoblasts by itself and exerted additive effects when used in combination with suboptimal amounts of interleukin 2. Furthermore, the purified protein was shown to synergize with low concentrations of interleukin 2 in causing the induction of lymphokine-activated killer cells.The potential utility of cytokines in the treatment of neoplasia and as immunoenhancing agents has recently been demonstrated in studies using human recombinant interleukin 2 (rIL-2) (1-6). However, the clinical use of rIL-2 has been complicated by the serious side effects that it may cause (2, 3). One approach to improving the efficacy of cytokine therapy while reducing toxicity is to use two or more cytokines in combination. For example, synergistic antitumor activity has been shown to result when rIL-2 is administered to tumor-bearing mice together with recombinant interferon a (rIFN-a) (7,8) or with recombinant tumor necrosis factor a (rTNF-a) (9). The antitumor effects of rIL-2 are thought to be mediated by host cytotoxic effector lymphocytes, which are activated by rIL-2 in vivo (10). rIFN-a (11) and rTNF-a (12, 13) have been shown to synergize with rIL-2 in activating cytotoxic effector cells in vitro as well as to exert synergistic antitumor effects when given in combination with rIL-2 in vivo (7-9). Hence, a cytokine was sought that could synergize with rIL-2 to activate cytotoxic lymphocytes in vitro and thus might also have utility as an antitumor agent when administered in combination with rIL-2 in vivo.Previously we demonstrated that IL-2-depleted lymphokine-containing cell supernatant solutions from cultures of human peripheral blood lymphocytes activated with phytohemagglutinin (PHA) or in mixed lymphocyte cultures contained such a factor, provisionally called cytotoxic lymphocyte maturation factor (CLMF) (14, 15). However, the quantities of human CLMF produced by peripheral blood lymphocytes were too low to permit its purification to homogeneity. Therefore, human lymphoid cell lines were screened for the production of cytokines that could synergize with rIL-2 to a...

A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

“…7 IL12 is among the most effective cytokines for stimulating antitumor immunity. 8,9 It enhances the proliferation and lytic activity of Th1/Tc1 T cells and natural killer cells, in part by inducing the expression of cytokines, such as IFNg. 10 The in vivo antitumor activity of IL12 is also mediated by induction of IFNg and by inhibition of angiogenesis.…”

Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma

“…6,7 This cytokine is a key participant in a variety of immune activities including the stimulation of T cells and natural killer (NK) cells and the regulation of cell adhesion molecules. [6][7][8] In addition to its immune-stimulating capacity, IL-12 has also been shown to be antiangiogenic.…”

“…6,7 This cytokine is a key participant in a variety of immune activities including the stimulation of T cells and natural killer (NK) cells and the regulation of cell adhesion molecules. [6][7][8] In addition to its immune-stimulating capacity, IL-12 has also been shown to be antiangiogenic. 9 Significant antitumor activity has been demonstrated in several animal models, [10][11][12] and clinical trials have indicated the potential antitumor activity of this cytokine.…”

Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12

“…IL-12 [16][17][18][19][20] augments proliferation and cytotoxic activity of T and NK cells, induces IFN-␥ production and facilitates T helper type 1 (Th1) response. In vivo administration of rIL-12 to mice not only induces specific CTL response, 21 but also results in reduction of experimental pulmonary and hepatic metastases of various tumors.…”